Search for a report

Reports

  • You are here:
  • Home
  • Downloads
  • EUROPE IMMUNOGLOBULIN MARKET FORECAST 2022-2030

EUROPE IMMUNOGLOBULIN MARKET FORECAST 2022-2030

The Europe immunoglobulin market is estimated to develop with a CAGR of 6.90% over the forecast period of 2022 to 2030, reaching a revenue share of $6209.33 million by 2030.

EUROPE IMMUNOGLOBULIN MARKET FORECAST 2022-2030

Europe Immunoglobulin Market by Product (IGG, IGA, IGM, IGE, IGD) Market by Mode of Delivery (Intravenous Immunoglobulin, Subcutaneous Immunoglobulin, Intramuscular Immunoglobulin) Market by Application (Hypogamma Globulinemia, Chronic Inflammatory Demyelinating Polyneuropathy, Primary Immunodeficiency Diseases, Myasthenia Gravis, Multifocal Motor Neuropathy, Idiopathic Thrombocytopenic Purpura (ITB), Inflammatory Myopathies, Specific Antibody Deficiency, Guillain-Barre Syndrome, Other Applications) Market by Distribution Channel (Hospital Pharmacy, Specialty Pharmacy, Other Distribution Channels) Market by End-user (Hospitals & Clinics, Homecare) by Geography

Request free sample

The Europe immunoglobulin market is estimated to develop with a CAGR of 6.90% over the forecast period of 2022 to 2030, reaching a revenue share of $6209.33 million by 2030.

The market growth of the region is reinforced by the prevalence of different immunodeficiency diseases, supportive government initiatives for immunoglobulin and plasma donation, as well as the growth of the biotechnology sector. However, the Europe immunoglobulin market may be restrained due to challenges faced by key players in the development of improved solutions for monitoring disease progression and patient response.

Europe Immunoglobulin Market

To know more about this report, request a free sample copy

The Europe immunoglobulin market growth study entails the analysis of the United Kingdom, France, Germany, Spain, Italy, Nordic Countries, and Rest of Europe. As per the National Center for Biotechnology Information, primary immunodeficiencies are rare diseases with a reported prevalence of between 1:16 000 and 1:50 000 in the United Kingdom. The improved recognition of primary immunodeficiencies and advances in molecular diagnostics have led to a significant identification rate, with nearly 300 genes being recognized. The nation’s government is also extending significant support for the adoption of immunoglobulin. For example, in 2021, the government authorized people to donate blood plasma for medicinal use for the first time in over two decades. The plasma collected by NHS Blood and Transplant (NHSBT) at 14 sites will primarily be utilized for the production of immunoglobulins.

On the other hand, research and development activities in the field of antibodies, in addition to government support by means of policies and programs, are among the major growth facilitators for the immunoglobulin market in Germany. In this regard, German scientists began a nationwide antibody study in 2020 to acquire a better understanding of the actual prevalence of the novel coronavirus in the country’s population. They also tested how well the measures to prevent the virus’ spread are working. Hence, these factors are playing an essential role in influencing the Europe immunoglobulin market growth over the forecast years.

The Europe immunoglobulin market is segmented into product, mode of delivery, application, distribution channel, and end-user. The mode of delivery category is further classified into intravenous immunoglobulin, subcutaneous immunoglobulin, and intramuscular immunoglobulin. Intravenous immunoglobulin refers to blood products prepared from the serum of nearly 1,000 to 15,000 donors per batch. Moreover, it is also the treatment of choice for patients experiencing antibody deficiencies. The United States Food and Drug Administration (FDA) is granting approvals to products as well as treatments involving intravenous immunoglobulin. For instance, in 2021, the FDA approved Pfizer Inc’s supplemental Biologics License Application for PANZYGA® (Immune Globulin Intravenous [Human] – ifas 10% Liquid Preparation).

Conversely, subcutaneous immunoglobulin is characterized by the preparation of human immunoglobulin for subcutaneous use. In this mode of delivery, an injection needle is inserted just under the patient’s skin.

Key players operating in the Europe immunoglobulin market are LFB Group, Grifols SA, Biotest AG, etc.

LFB Group, headquartered in France, is a biopharmaceutical group engaged in the development, marketing, and manufacturing of various medicinal products for treating a range of serious and often rare diseases across major therapeutic fields. These include immunology, intensive care, and hemostasis.

The company’s product IQYMUNE® is a 10% liquid intravenous immunoglobulin. It enables clinicians to treat rare immunity diseases, including genetic disorders, such as immunologic thrombocytopenic purpura and others.

Report Synopsis

Report Scope Details
Market Forecast Years 2022-2030
Base Year 2021
Market Historical Years 2018-2021
Forecast Units Revenue ($ Million)
Segments Analyzed Product, Mode of Delivery, Application, Distribution Channel, End-User
Countries Analyzed United Kingdom, France, Germany, Spain, Italy, Nordic Countries, and Rest of Europe
Companies Analyzed

Biotest AG, China Biologic Products Inc, Grifols SA, LFB Group, CSL Behring, Kedrion, Octapharma AG, Takeda Pharmaceutical Company Limited, Bio Products Laboratory, Shanghai RAAS Blood Products Co Ltd, Pfizer Inc, Sanquin Plasma Products BV, ADMA Biologics, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd, Kamada Ltd

To request a free sample copy of this report, please complete the form below:

We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


    1. RESEARCH SCOPE & METHODOLOGY
      • STUDY OBJECTIVES
      • SCOPE OF STUDY
      • METHODOLOGY
      • ASSUMPTIONS & LIMITATIONS
    2. EXECUTIVE SUMMARY
      • MARKET SIZE & ESTIMATES
      • MARKET OVERVIEW
    3. MARKET DYNAMICS
      • KEY DRIVERS
        • GROWTH IN GERIATRIC POPULATION
        • PREVALENCE OF IMMUNODEFICIENCY DISEASES AND AUTOIMMUNE DISORDERS
        • INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
      • KEY RESTRAINTS
        • HIGH COST OF THERAPY
        • HIGH RISK OF SIDE EFFECTS
    1. KEY ANALYTICS
      • IMPACT OF COVID-19 ON IMMUNOGLOBULIN MARKET
      • KEY MARKET TRENDS
      • PORTER’S FIVE FORCES ANALYSIS
        • BUYERS POWER
        • SUPPLIERS POWER
        • SUBSTITUTION
        • NEW ENTRANTS
        • INDUSTRY RIVALRY
      • OPPORTUNITY MATRIX
      • VENDOR LANDSCAPE
      • KEY BUYING CRITERIA
        • SOURCE
        • APPLICATION
        • EPITOPE
        • VALIDATION
    1. MARKET BY PRODUCT
      • IGG
      • IGA
      • IGM
      • IGE
      • IGD
    2. MARKET BY MODE OF DELIVERY
      • INTRAVENOUS IMMUNOGLOBULIN
      • SUBCUTANEOUS IMMUNOGLOBULIN
      • INTRAMUSCULAR IMMUNOGLOBULIN
    3. MARKET BY APPLICATION
      • HYPOGAMMA GLOBULINEMIA
      • CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
      • PRIMARY IMMUNODEFICIENCY DISEASES
      • MYASTHENIA GRAVIS
      • MULTIFOCAL MOTOR NEUROPATHY
      • IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
      • INFLAMMATORY MYOPATHIES
      • SPECIFIC ANTIBODY DEFICIENCY
      • GUILLAIN-BARRE SYNDROME
      • OTHER APPLICATIONS
    4. MARKET BY DISTRIBUTION CHANNEL
      • HOSPITAL PHARMACY
      • SPECIALTY PHARMACY
      • OTHER DISTRIBUTION CHANNELS
    5. MARKET BY END-USER
      • HOSPITALS & CLINICS
      • HOMECARE
    6. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • SPAIN
          • ITALY
          • NORDIC COUNTRIES
          • REST OF EUROPE
    1. COMPETITIVE LANDSCAPE
      • KEY STRATEGIC DEVELOPMENTS
        • MERGERS & ACQUISITIONS
        • PRODUCT LAUNCHES & DEVELOPMENTS
        • PARTNERSHIPS & AGREEMENTS
        • BUSINESS EXPANSIONS & DIVESTITURES
      • COMPANY PROFILES
        • ADMA BIOLOGICS
        • BIO PRODUCTS LABORATORY
        • BIOTEST AG
        • CHINA BIOLOGIC PRODUCTS INC
        • CSL BEHRING
        • GRIFOLS SA
        • KAMADA LTD
        • KEDRION BIOPHARMA
        • LFB GROUP
        • OCTAPHARMA AG
        • PFIZER INC
        • SANQUIN PLASMA PRODUCTS BV
        • SHANGHAI RAAS BLOOD PRODUCTS CO LTD
        • SICHUAN YUANDA SHUYANG PHARMACEUTICAL CO LTD
        • TAKEDA PHARMACEUTICAL COMPANY LIMITED

    LIST OF TABLES

    TABLE 1: MARKET SNAPSHOT – IMMUNOGLOBULIN

    TABLE 2: EUROPE IMMUNOGLOBULIN MARKET, BY PRODUCT, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 3: EUROPE IMMUNOGLOBULIN MARKET, BY PRODUCT, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 4: EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 5: EUROPE IMMUNOGLOBULIN MARKET, BY MODE OF DELIVERY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 6: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 7: EUROPE IMMUNOGLOBULIN MARKET, BY APPLICATION, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 8: EUROPE IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 9: EUROPE IMMUNOGLOBULIN MARKET, BY DISTRIBUTION CHANNEL, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 10: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 11: EUROPE IMMUNOGLOBULIN MARKET, BY END-USER, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 12: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2021 (IN $ MILLION)

    TABLE 13: EUROPE IMMUNOGLOBULIN MARKET, BY COUNTRY, FORECAST YEARS, 2022-2030 (IN $ MILLION)

    TABLE 14: LEADING PLAYERS OPERATING IN EUROPE IMMUNOGLOBULIN MARKET

    TABLE 15: LIST OF MERGERS & ACQUISITIONS

    TABLE 16: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS

    TABLE 17: LIST OF PARTNERSHIPS & AGREEMENTS

    TABLE 18: LIST OF BUSINESS EXPANSIONS & DIVESTITURES          

    LIST OF FIGURES

    FIGURE 1: KEY MARKET TRENDS

    FIGURE 2: PORTER’S FIVE FORCES ANALYSIS

    FIGURE 3: OPPORTUNITY MATRIX

    FIGURE 4: VENDOR LANDSCAPE

    FIGURE 5: KEY BUYING CRITERIA

    FIGURE 6: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY PRODUCT, IN 2021

    FIGURE 7: EUROPE IMMUNOGLOBULIN MARKET, BY IGG, 2022-2030 (IN $ MILLION)

    FIGURE 8: EUROPE IMMUNOGLOBULIN MARKET, BY IGA, 2022-2030 (IN $ MILLION)

    FIGURE 9: EUROPE IMMUNOGLOBULIN MARKET, BY IGM, 2022-2030 (IN $ MILLION)

    FIGURE 10: EUROPE IMMUNOGLOBULIN MARKET, BY IGE, 2022-2030 (IN $ MILLION)

    FIGURE 11: EUROPE IMMUNOGLOBULIN MARKET, BY IGD, 2022-2030 (IN $ MILLION)

    FIGURE 12: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY MODE OF DELIVERY, IN 2021

    FIGURE 13: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAVENOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

    FIGURE 14: EUROPE IMMUNOGLOBULIN MARKET, BY SUBCUTANEOUS IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

    FIGURE 15: EUROPE IMMUNOGLOBULIN MARKET, BY INTRAMUSCULAR IMMUNOGLOBULIN, 2022-2030 (IN $ MILLION)

    FIGURE 16: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY APPLICATION, IN 2021

    FIGURE 17: EUROPE IMMUNOGLOBULIN MARKET, BY HYPOGAMMA GLOBULINEMIA, 2022-2030 (IN $ MILLION)

    FIGURE 18: EUROPE IMMUNOGLOBULIN MARKET, BY CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY, 2022-2030 (IN $ MILLION)

    FIGURE 19: EUROPE IMMUNOGLOBULIN MARKET, BY PRIMARY IMMUNODEFICIENCY DISEASES, 2022-2030 (IN $ MILLION)

    FIGURE 20: EUROPE IMMUNOGLOBULIN MARKET, BY MYASTHENIA GRAVIS, 2022-2030 (IN $ MILLION)

    FIGURE 21: EUROPE IMMUNOGLOBULIN MARKET, BY MULTIFOCAL MOTOR NEUROPATHY, 2022-2030 (IN $ MILLION)

    FIGURE 22: EUROPE IMMUNOGLOBULIN MARKET, BY IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP), 2022-2030 (IN $ MILLION)

    FIGURE 23: EUROPE IMMUNOGLOBULIN MARKET, BY INFLAMMATORY MYOPATHIES, 2022-2030 (IN $ MILLION)

    FIGURE 24: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIFIC ANTIBODY DEFICIENCY, 2022-2030 (IN $ MILLION)

    FIGURE 25: EUROPE IMMUNOGLOBULIN MARKET, BY GUILLAIN-BARRE SYNDROME, 2022-2030 (IN $ MILLION)

    FIGURE 26: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER APPLICATIONS, 2022-2030 (IN $ MILLION)

    FIGURE 27: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY DISTRIBUTION CHANNEL, IN 2021

    FIGURE 28: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITAL PHARMACY, 2022-2030 (IN $ MILLION)

    FIGURE 29: EUROPE IMMUNOGLOBULIN MARKET, BY SPECIALTY PHARMACY, 2022-2030 (IN $ MILLION)

    FIGURE 30: EUROPE IMMUNOGLOBULIN MARKET, BY OTHER DISTRIBUTION CHANNELS, 2022-2030 (IN $ MILLION)

    FIGURE 31: EUROPE IMMUNOGLOBULIN MARKET, GROWTH POTENTIAL, BY END-USER, IN 2021

    FIGURE 32: EUROPE IMMUNOGLOBULIN MARKET, BY HOSPITALS & CLINICS, 2022-2030 (IN $ MILLION)

    FIGURE 33: EUROPE IMMUNOGLOBULIN MARKET, BY HOMECARE, 2022-2030 (IN $ MILLION)

    FIGURE 34: EUROPE IMMUNOGLOBULIN MARKET, COUNTRY OUTLOOK, 2021 & 2030 (IN %)

    FIGURE 35: UNITED KINGDOM IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 36: GERMANY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 37: FRANCE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 38: SPAIN IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 39: ITALY IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 40: NORDIC COUNTRIES IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)

    FIGURE 41: REST OF EUROPE IMMUNOGLOBULIN MARKET, 2022-2030 (IN $ MILLION)       

    1. GEOGRAPHICAL ANALYSIS
      • EUROPE
        • MARKET SIZE & ESTIMATES
        • KEY GROWTH ENABLERS
        • KEY CHALLENGES
        • KEY PLAYERS
        • COUNTRY ANALYSIS
          • UNITED KINGDOM
          • GERMANY
          • FRANCE
          • SPAIN
          • ITALY
          • NORDIC COUNTRIES
          • REST OF EUROPE
    1. MARKET BY PRODUCT
      • IGG
      • IGA
      • IGM
      • IGE
      • IGD
    2. MARKET BY MODE OF DELIVERY
      • INTRAVENOUS IMMUNOGLOBULIN
      • SUBCUTANEOUS IMMUNOGLOBULIN
      • INTRAMUSCULAR IMMUNOGLOBULIN
    3. MARKET BY APPLICATION
      • HYPOGAMMA GLOBULINEMIA
      • CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY
      • PRIMARY IMMUNODEFICIENCY DISEASES
      • MYASTHENIA GRAVIS
      • MULTIFOCAL MOTOR NEUROPATHY
      • IDIOPATHIC THROMBOCYTOPENIC PURPURA (ITP)
      • INFLAMMATORY MYOPATHIES
      • SPECIFIC ANTIBODY DEFICIENCY
      • GUILLAIN-BARRE SYNDROME
      • OTHER APPLICATIONS
    4. MARKET BY DISTRIBUTION CHANNEL
      • HOSPITAL PHARMACY
      • SPECIALTY PHARMACY
      • OTHER DISTRIBUTION CHANNELS
    5. MARKET BY END-USER
      • HOSPITALS & CLINICS
      • HOMECARE

    To request a free sample copy of this report, please complete the form below :

    We offer 10% free customization including country-level data, niche applications and competitive landscape with every report.


      Choose License Type

      Buy Now